• Climb
    • Everest Base Camp trek
    • Kilimanjaro Climb
    • Mt. Everest
  • Speaking
  • About
    • Frontpoints
    • Podcast
    • Events
    • Internships
    • Team
      • David Shaywitz
      • Alex Harding
      • Stephanie Barnes
      • Pedro Rafael Rosado
      • Steve White
    • Hood Biography
    • In the News
    • Testimonials
  • Community
  • COVID-19
  • Contact
  • Subscribe
    • Individual Subscriptions
    • Group Subscriptions
Your Edge In Biotech.
  • Climb
    • Everest Base Camp trek
    • Kilimanjaro Climb
    • Mt. Everest
  • Speaking
  • About
    • Frontpoints
    • Podcast
    • Events
    • Internships
    • Team
      • David Shaywitz
      • Alex Harding
      • Stephanie Barnes
      • Pedro Rafael Rosado
      • Steve White
    • Hood Biography
    • In the News
    • Testimonials
  • Community
  • COVID-19
  • Contact
  • Subscribe
    • Individual Subscriptions
    • Group Subscriptions
6
Apr
2015

Baseball Meets Biotech, Where Hope Springs Eternal

/
Luke Timmerman
/
1
/
All, Cancer, Drugs, The Edge
06 Apr 2015

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
4
Apr
2015

Will We Just Give Up on Federal Funding for Research? I Sure Hope Not

/
Luke Timmerman
/
0
/
All, Cancer
04 Apr 2015

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
3
Apr
2015

Sarepta’s Controversial CEO is Out, But Duchenne Muscular Dystrophy R&D is Rising

/
Luke Timmerman
/
3
/
All, Drugs, FDA
03 Apr 2015

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
30
Mar
2015

Cancer Combos Are the Way Forward. Will Drugmakers Put Patients First?

/
Luke Timmerman
/
2
/
All, Cancer, Drugs, The Edge
30 Mar 2015

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
26
Mar
2015

See the Photos: Timmerman Report West Coast Launch Party

/
Luke Timmerman
/
2
/
All, People
26 Mar 2015

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
24
Mar
2015

Come to Pfizer Cambridge for the East Coast Launch Party

/
Luke Timmerman
/
0
/
All
24 Mar 2015

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
23
Mar
2015

Company Subscriptions: You Asked, and You Will Get

/
Luke Timmerman
/
0
/
All, People
23 Mar 2015

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
23
Mar
2015

Salaries are Inching Up in the Biotech Boom, Not Booming

/
Luke Timmerman
/
1
/
All, People, The Edge
23 Mar 2015

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
20
Mar
2015

NASH is the Next Monster Pharmaceutical Market. Here Are The Players

/
Luke Timmerman
/
4
/
All, Drugs, Strategy
20 Mar 2015

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
18
Mar
2015

Third Rock’s Revolution Medicines Tears Apart Antifungals, Atom By Atom

/
Luke Timmerman
/
0
/
All, Drugs, Venture Capital
18 Mar 2015

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
16
Mar
2015

The Top 20 Early-Stage Biotech Investors (And 2 Resuscitated By the Boom)

/
Luke Timmerman
/
4
/
All, Finance, The Edge
16 Mar 2015

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
13
Mar
2015

Ember Therapeutics, After Shutting Down, Pools IP With Mariel

/
Luke Timmerman
/
0
/
All, Drugs
13 Mar 2015

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
12
Mar
2015

Antibiotic R&D Is Getting More Attention. Who’s Doing What?

/
Luke Timmerman
/
6
/
All, Drugs, FDA, Strategy
12 Mar 2015

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
9
Mar
2015

2015 Power Rankings: Biotech Investment Banks

/
Luke Timmerman
/
2
/
All, Finance, The Edge
09 Mar 2015

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
6
Mar
2015

Esperion Jockeys For Place Between Statins and the Next Big Class of Heart Drugs

/
Luke Timmerman
/
0
/
All, Drugs, Strategy
06 Mar 2015

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
3
Mar
2015

Come Celebrate at the Timmerman Report Launch Party

/
Luke Timmerman
/
0
/
All, People
03 Mar 2015

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
2
Mar
2015

Margaret Hamburg: One of the Best Commissioners in FDA History

/
Luke Timmerman
/
3
/
All, FDA, People
02 Mar 2015

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
25
Feb
2015

The Tularik Alumni: Where Are They Now?

/
Luke Timmerman
/
0
/
All, Cancer, Drugs, People
25 Feb 2015

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
23
Feb
2015

Who Is Poised To Go Public in 2015, and Who Isn’t?

/
Luke Timmerman
/
2
/
All, Drugs, Finance, Strategy, The Edge, Venture Capital
23 Feb 2015

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
20
Feb
2015

Five Things to Watch at Next Week’s Big Genomics Show

/
Luke Timmerman
/
1
/
All, Cancer, Diagnostics, FDA, Genomics, Science
20 Feb 2015

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
‹ Previous 1 … 44 45 46 47 Next ›

Get In-depth Biotech Coverage with Timmerman Report.

Individual Subscription

Group Subscription

Or: Sign in to your account

Your account

Sign in

The Long Run Podcast

The Long Run Podcast

Sponsored By
Synthego

What Readers Are Saying

testimonial
testimonial
testimonial

View More Testimonials ➛

Twitter

Tweets by ldtimmerman Follow @ldtimmerman
© Copyright 2021, TimmermanReport.com
Privacy Policy | Terms of Use
Custom WordPress site by: Perception Builder